We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Codexis Inc (CDXS) USD0.0001

Sell:$3.44 Buy:$3.45 Change: $0.26 (7.01%)
NASDAQ:2.77%
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Sell:$3.44
Buy:$3.45
Change: $0.26 (7.01%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Sell:$3.44
Buy:$3.45
Change: $0.26 (7.01%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

Contact details

Address:
200 Penobscot Dr
REDWOOD CITY
94063-4718
United States
Telephone:
+1 (650) 4218100
Website:
https://www.codexis.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CDXS
ISIN:
US1920051067
Market cap:
$230.72 million
Shares in issue:
70.56 million
Sector:
Life Sciences Tools & Services
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Stephen Dilly
    President, Chief Executive Officer, Director
  • Sriram Ryali
    Chief Financial Officer
  • Kevin Norrett
    Chief Operating Officer
  • Margaret Fitzgerald
    Chief Legal and Compliance Officer, General Counsel and Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.